On July 2, 2018, Calmare Therapeutics Incorporated announced that the following proposals were not approved by the shareholders at the 2018 annual shareholders meeting: (i) removal of 4 of the 5 current directors: Conrad Mir, Peter Brennan, Rustin Howard, and Carl O’Connell and (ii) to elect Stanley Yarbro, Robert Conway, Steve Roehrich, Robert Davis, and Benjamin Large as directors of the Company.